112 reports of this reaction
1.2% of all IVACAFTOR reports
#17 most reported adverse reaction
HAEMOPTYSIS is the #17 most commonly reported adverse reaction for IVACAFTOR, manufactured by Vertex Pharmaceuticals Incorporated. There are 112 FDA adverse event reports linking IVACAFTOR to HAEMOPTYSIS. This represents approximately 1.2% of all 9,200 adverse event reports for this drug.
Patients taking IVACAFTOR who experience haemoptysis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMOPTYSIS is a less commonly reported adverse event for IVACAFTOR, but still significant enough to appear in the safety profile.
In addition to haemoptysis, the following adverse reactions have been reported for IVACAFTOR:
The following drugs have also been linked to haemoptysis in FDA adverse event reports:
HAEMOPTYSIS has been reported as an adverse event in 112 FDA reports for IVACAFTOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMOPTYSIS accounts for approximately 1.2% of all adverse event reports for IVACAFTOR, making it a notable side effect.
If you experience haemoptysis while taking IVACAFTOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.